Total Payments
$5,388
2024 Payments
$1,990
Companies
46
Transactions
265
Medicare Patients
1,777
Medicare Billing
$140,387
Payment Breakdown by Category
Food & Beverage$5,339 (99.1%)
Education$48.24 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,339 | 262 | 99.1% |
| Education | $48.24 | 3 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Exelixis Inc. | $513.65 | 5 | $0 (2024) |
| Merck Sharp & Dohme LLC | $451.56 | 22 | $0 (2024) |
| Amgen Inc. | $396.76 | 23 | $0 (2023) |
| PFIZER INC. | $285.84 | 18 | $0 (2024) |
| Eisai Inc. | $273.56 | 12 | $0 (2024) |
| Incyte Corporation | $269.48 | 15 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $227.36 | 13 | $0 (2024) |
| Janssen Biotech, Inc. | $197.70 | 12 | $0 (2024) |
| Gilead Sciences, Inc. | $191.50 | 11 | $0 (2024) |
| Genentech USA, Inc. | $179.11 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,990 | 102 | Merck Sharp & Dohme LLC ($229.74) |
| 2023 | $1,686 | 62 | Exelixis Inc. ($436.50) |
| 2022 | $732.44 | 40 | Amgen Inc. ($90.14) |
| 2021 | $979.54 | 61 | Amgen Inc. ($249.78) |
All Payment Transactions
265 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $17.18 | General |
| Category: Hematology/Oncology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $10.85 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: Oncology | ||||||
| 12/11/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $7.21 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/27/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $34.88 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: CELLT | ||||||
| 11/19/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/15/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: Oncology | ||||||
| 11/12/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $21.03 | General |
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Education | In-kind items and services | $25.95 | General |
| Category: Oncology | ||||||
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $23.37 | General |
| 10/30/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $21.59 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $20.71 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 10/22/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.20 | General |
| Category: Hematology/Oncology | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: Oncology | ||||||
| 10/17/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: ONCOLOGY | ||||||
| 10/15/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $29.33 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 369 | 645 | $66,626 | $34,605 |
| 2022 | 5 | 435 | 653 | $70,312 | $34,977 |
| 2021 | 5 | 501 | 777 | $78,009 | $39,191 |
| 2020 | 5 | 472 | 770 | $77,813 | $31,614 |
Total Patients
1,777
Total Services
2,845
Medicare Billing
$140,387
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 198 | 440 | $52,430 | $26,621 | 50.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 137 | 163 | $12,714 | $6,850 | 53.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 14 | 15 | $780.00 | $584.08 | 74.9% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2023 | 20 | 27 | $702.00 | $549.43 | 78.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 191 | 379 | $45,263 | $23,609 | 52.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 190 | 214 | $16,744 | $8,519 | 50.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 13 | $6,563 | $1,592 | 24.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 20 | 20 | $1,040 | $754.80 | 72.6% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 22 | 27 | $702.00 | $502.68 | 71.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 207 | 400 | $47,837 | $24,787 | 51.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 247 | 326 | $25,688 | $12,686 | 49.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 17 | $3,080 | $827.22 | 26.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 13 | 14 | $780.00 | $510.84 | 65.5% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2021 | 19 | 20 | $624.00 | $379.39 | 60.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 208 | 413 | $49,460 | $20,276 | 41.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 222 | 307 | $24,258 | $9,754 | 40.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 16 | $2,899 | $792.12 | 27.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 12 | 12 | $624.00 | $419.48 | 67.2% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 19 | 22 | $572.00 | $373.26 | 65.3% |
About Laura Eichenlaub, NP-C
Laura Eichenlaub, NP-C is a Family healthcare provider based in Mount Vernon, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/09/2016. The National Provider Identifier (NPI) number assigned to this provider is 1063870715.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Laura Eichenlaub, NP-C has received a total of $5,388 in payments from pharmaceutical and medical device companies, with $1,990 received in 2024. These payments were reported across 265 transactions from 46 companies. The most common payment nature is "Food and Beverage" ($5,339).
As a Medicare-enrolled provider, Eichenlaub has provided services to 1,777 Medicare beneficiaries, totaling 2,845 services with total Medicare billing of $140,387. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Mount Vernon, OH
- Active Since 02/09/2016
- Last Updated 02/09/2016
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1063870715
Products in Payments
- CABOMETYX (Drug) $513.65
- KEYTRUDA (Biological) $451.56
- Lenvima (Drug) $273.56
- Udenyca (Biological) $175.32
- LIBTAYO (Biological) $167.08
- Nplate (Biological) $162.49
- JAKAFI (Drug) $156.59
- ZEPZELCA (Drug) $137.65
- IBRANCE (Drug) $136.52
- VERZENIO (Drug) $132.24
- LUMAKRAS (Drug) $127.15
- Rezlidhia (Drug) $121.06
- Enhertu (Drug) $107.23
- ERLEADA (Drug) $103.55
- Alecensa (Biological) $95.10
- IMBRUVICA (Drug) $95.06
- XALKORI (Drug) $94.44
- Kyprolis (Drug) $89.24
- MONJUVI (Drug) $85.90
- PADCEV (Biological) $83.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Mount Vernon
Mrs. Amanda Mckee, Msn, Fnp, MSN, FNP
Family — Payments: $217,153
Family $217,153
Ms. Vicki Chapman
Family — Payments: $50,014
Family $50,014
Keirsten Montgomery, Rn, Bsn, Fnp-C, RN, BSN, FNP-C
Family — Payments: $12,016
Family $12,016
Ms. Barbara Lynch, Fnp, FNP
Family — Payments: $8,811
Family $8,811
Mr. Larry Weckesser, Aprn, APRN
Family — Payments: $6,920
Family $6,920
Ramonda Dugas, Np, NP
Family — Payments: $5,148
Family $5,148